Most public discussion of “THC” refers to Δ⁹-trans-tetrahydrocannabinol — the major intoxicating cannabinoid in Cannabis sativa. Δ⁹-cis-tetrahydrocannabinol (cis-THC) is its less-publicized stereoisomer: a structurally similar molecule that differs only in the spatial arrangement of two hydrogen atoms at the ring junction. Until recently, cis-THC was considered a synthetic curiosity. A 2021 paper definitively demonstrated that it occurs naturally in cannabis, particularly in fiber-hemp varieties, which has reignited research interest.
This article reviews what the peer-reviewed literature actually shows about cis-THC: where it comes from, how its pharmacology compares to the more familiar trans-THC, and what is and is not known about its biological activity.
What Is cis-THC?
Δ⁹-cis-tetrahydrocannabinol (cis-THC) is a stereoisomer of Δ⁹-trans-THC. Both molecules share the same molecular formula (C₂₁H₃₀O₂) and the same connectivity of atoms; they differ only in the cis-versus-trans orientation of the hydrogens at the 6a and 10a positions of the tricyclic ring system (Schafroth et al., 2021).
In nature, the trans isomer is overwhelmingly dominant. cis-THC has historically been treated as a synthetic byproduct or a forensic anomaly rather than a meaningful natural cannabinoid. That perception changed in 2021, when Schafroth and colleagues published a comprehensive analysis confirming that natural cis-THC occurs in measurable amounts in certain fiber-hemp varieties registered in Europe and in research accessions of Cannabis sativa (Schafroth et al., 2021).
Chirality: A Subtle but Important Difference
Naturally occurring trans-THC is essentially a single enantiomer: (−)-Δ⁹-trans-THC, with absolute configuration 6aR,10aR. This stereochemistry is what enables tight binding to the CB1 receptor and produces psychoactive effects.
cis-THC, by contrast, occurs in cannabis in a scalemic form — that is, an enantiomerically enriched but not perfectly pure mixture, typically 80–90% enantiomeric excess of one form over the other (Schafroth et al., 2021). The major enantiomer in natural samples has been established as (−)-Δ⁹-cis-THC, with absolute configuration 6aS,10aR.
This stereochemical detail matters because cannabinoid receptors are highly stereoselective. A small change in three-dimensional arrangement at the ring junction can dramatically affect whether a molecule fits the binding pocket, and how strongly.
Pharmacology: Substantially Weaker Than trans-THC
Direct receptor-binding and functional data on cis-THC have been generated in recent work. Schafroth et al. (2021) reported that:
- (−)-Δ⁹-cis-THC showed approximately 10-fold lower binding affinities at both CB1 and CB2 receptors compared to the natural trans-isomer.
- (+)-Δ⁹-cis-THC was essentially inactive in both assays, with binding and functional activity only at high micromolar concentrations.
These quantitative findings are consistent with much older qualitative reports. As early as 1971, Mechoulam observed that racemic synthetic Δ⁹-cis-THC was inactive in behavioral tests in rhesus monkeys, and follow-up work in the mid-1970s by Razdan and Martin found that (+)-Δ⁹-cis-THC was largely inactive in behavioral assays in dogs, with potencies reduced about 100-fold compared with (−)-Δ⁹-trans-THC (cited in Schafroth et al., 2021).
The take-home: cis-THC is a real cannabinoid, but it is substantially less active at cannabinoid receptors than the familiar trans-THC. Whether the small amounts present in cannabis material contribute meaningfully to overall pharmacological effects in any given product is unclear.
Practical Implications
The natural occurrence of cis-THC has several practical consequences:
Forensic and analytical chemistry. Distinguishing cis-THC from trans-THC requires chiral chromatography — standard cannabinoid panels using achiral columns may co-elute the two. Mistaking cis-THC for trans-THC could overestimate intoxicating cannabinoid content in low-THC fiber hemp (Schafroth et al., 2021).
Hemp regulation. In jurisdictions where total Δ⁹-THC is the legal threshold for hemp versus marijuana classification, the question of whether cis-THC counts toward that threshold has not been uniformly addressed. As awareness of natural cis-THC increases, regulatory and analytical practices may need to be updated.
Research interest. Because cis-THC appears to be a weaker, less-stereoselective version of trans-THC, it is of medicinal-chemistry interest as a probe for understanding how stereochemistry shapes cannabinoid receptor activation. Synthetic chemists also use cis-THC as a substrate for further structural modifications.
Pharmacokinetics and Human Data
There are no published clinical trials of isolated cis-THC in humans. Pharmacokinetic data are limited to what can be inferred from natural-product analyses of cannabis material containing both isomers.
This means that questions which have been carefully studied for trans-THC — absorption rate, peak plasma concentration, metabolism by CYP enzymes, half-life, route-of-administration differences — have not been independently characterized for cis-THC. It is generally assumed that the two isomers behave similarly in absorption and metabolism, but this is an assumption, not a measurement.
Safety and Regulatory Considerations
Direct safety data on cis-THC in humans are absent. However:
- cis-THC’s lower CB1 affinity suggests that, on a milligram-for-milligram basis, it is unlikely to produce the same intensity of intoxication as trans-THC.
- The stereoisomer’s status under controlled-substance schedules varies by jurisdiction. In the United States, the Controlled Substances Act language refers to “tetrahydrocannabinols” without specifying isomer, and DEA guidance has historically been read to encompass all THC isomers — but this is an area of active legal interpretation.
- Cannabis products containing measurable cis-THC alongside trans-THC will typically be subject to whatever regulations apply to their trans-THC content.
The U.S. Food and Drug Administration has not approved cis-THC for any therapeutic indication. As with all cannabis-derived cannabinoids, anyone considering products containing cis-THC, particularly alongside prescription medications or in the context of a medical condition, should speak with a qualified medical professional first.
Frequently Asked Questions
Is cis-THC psychoactive?
In direct receptor-binding studies, (−)-Δ⁹-cis-THC has roughly 10-fold lower affinity at CB1 than the natural trans-isomer, and (+)-Δ⁹-cis-THC is essentially inactive (Schafroth et al., 2021). Older animal-behavior studies found cis-THC largely inactive at doses where trans-THC produced clear effects. On that basis, cis-THC is unlikely to produce strong intoxication at the trace amounts found in cannabis, though direct human dosing studies have not been performed.
Is cis-THC found naturally in cannabis?
Yes. Although it has long been treated as a synthetic curiosity, Schafroth et al. (2021) confirmed that cis-THC occurs naturally in measurable amounts in certain low-THC fiber-hemp varieties and research accessions of Cannabis sativa.
How is cis-THC different from Δ⁸-THC?
Δ⁸-THC and cis-THC are different in chemistry. Δ⁸-THC is a positional isomer in which a double bond has shifted from the 9,10 position to the 8,9 position; the trans/cis designation refers to a different molecular feature (the orientation of substituents at the ring junction). The two are independent variations on the THC scaffold and should not be confused.
Will cis-THC show up on a drug test?
This depends on the assay. Standard immunoassay screens often detect THC and its primary metabolite (THC-COOH) without distinguishing isomers, and confirmatory chiral chromatography is generally not part of routine workplace drug testing. People subject to drug testing should not assume that products advertised as “cis-THC” or “low-THC” are necessarily safe to use under their employer’s testing program.
References
Hanuš, L. O., Meyer, S. M., Muñoz, E., Taglialatela-Scafati, O., & Appendino, G. (2016). Phytocannabinoids: A unified critical inventory. Natural Product Reports, 33(12), 1357–1392. https://doi.org/10.1039/C6NP00074F
Schafroth, M. A., Mazzoccanti, G., Reynoso-Moreno, I., Erni, R., Pollastro, F., Caprioglio, D., Botta, B., Allegrone, G., Grassi, G., Chicca, A., Gasparrini, F., Gertsch, J., Carreira, E. M., & Appendino, G. (2021). Δ⁹-cis-Tetrahydrocannabinol: Natural occurrence, chirality, and pharmacology. Journal of Natural Products, 84(9), 2502–2510. https://doi.org/10.1021/acs.jnatprod.1c00513
